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Cytomegalovirus (CMV) infection does not usually produce symptoms when it causes
primary infection, reinfection, or reactivation because these three types of infection
are all controlled by the normal immune system. However, CMV becomes an impor-
tant pathogen in individuals whose immune system is immature or compromised, such
as the unborn child. Several vaccines against CMV are currently in clinical trials that
aim to induce immunity in seronegative individuals and/or to boost the immunity of
those with prior natural infection (seropositives). To facilitate estimation of the burden
of disease and the need for vaccines that induce de novo immune responses or that
boost pre‐existing immunity to CMV, we conducted a systematic survey of the pub-
lished literature to describe the global seroprevalence of CMV IgG antibodies. We esti-
mated a global CMV seroprevalence of 83% (95%UI: 78‐88) in the general population,
86% (95%UI: 83‐89) in women of childbearing age, and 86% (95%UI: 82‐89) in donors
of blood or organs. For each of these three groups, the highest seroprevalence was
seen in the World Health Organisation (WHO) Eastern Mediterranean region 90%
(95%UI: 85‐94) and the lowest in WHO European region 66% (95%UI: 56‐74). These
estimates of the worldwide CMV distribution will help develop national and regional
burden of disease models and inform future vaccine development efforts.
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Cytomegalovirus (CMV) is a common infection that has a complex nat-
ural history.1 Individuals without CMV infection may acquire primary
infection, and those with prior infection (seropositive) may reactivate
latent CMV or may become reinfected with a new strain of CMV.1 In- - - - - - - - - - - - - - - - - - - - - - - - - - -
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because the immune system keeps virus replication under control. How-
ever, in patients who are immunocompromised, CMV replication may
be uncontrolled and lead to high viral loads in the urine, which are asso-
ciated with viraemia, dissemination to multiple organs, and end‐organ
diseases such as pneumonitis, retinitis, hepatitis, or gastroenteritis.2
CMV is the most common intrauterine infection and a high priority for
vaccine development.3,4 Disease can occur when pregnant women have
active CMV infection with viraemia leading to involvement of the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 of 6 ZUHAIR ET AL.placenta and then the fetus.5 Intrauterine infection can occur following
primary infection, reactivation, or reinfection in a pregnant woman.6,7
In addition to these direct effects that can be seen in individuals
and documented histopathologically in biopsies of organs, CMV is
associated with indirect effects which are apparent at a population‐
level rather than an individual‐level. This phenomenon was first
described after solid organ transplant where an excess of graft rejec-
tion, atherosclerosis, and secondary bacterial or fungal infections was
seen among those with past history of detectable viraemia.8 These
indirect effects partly explain the survival disadvantage that is seen in
solid organ transplant or stem cell transplant patient populations who
are CMV seropositive.9 A recent randomized controlled trial showed
that stem cell transplant patients given prophylaxis with letermovir
had improved survival compared to recipients of placebo, so supporting
CMV as an underlying contributor to all‐cause mortality.10 Indirect
effects may also be seen in people living with HIV, manifesting as more
rapid progression to AIDS and/or death.11,12 Most recently, the indirect
effect of excess mortality has been defined in members of the general
population without classical risk factors for CMV disease.13,14
Given the complex natural history of CMV infection, the emerging
need to plan the evaluation of candidate vaccines15 against CMV (which
may be given to prevent primary infection and/or to the boost immu-
nity in those with natural infection) would be facilitated by knowledge
of the seroepidemiology of CMV around the world. We therefore con-
ducted a systematic literature search to identify the parts of the world
that have a relatively high burden of infection with this common virus.2 | MATERIALS AND METHODS
2.1 | Search strategy
A systematic review was conducted and reported in line with the criteria
set out by the PRISMA guidelines.16 We reviewed articles published
prior to 5 October 2016 in the databases Embase, Medline, Web of Sci-
ence, POPLINE, CINAHL Plus, LILACS, Africa Index Medicus, WHOLIS,
and OPENGREY. The use of OPENGREY allowed for a search of grey
data (unpublished data or data published in non‐commercial form).
In consultation with an expert medical librarian, we developed a
search strategy and adapted it to each database. A combination of
medical subject headings (MeSH) and free text searches was used to
search for terms relating to CMV and seroprevalence (full search strat-
egy available in Appendix A).
Publications were screened and catalogued on Endnote X6. A
strategy involving “auto‐search” and “hand‐search” was used to iden-
tify duplicates, before two authors (M.Z. and G.W.) systematically
screened the search results independently and applied the inclusion
and exclusion criteria.
In brief, studies that included data on CMV seroprevalence (based
on detection of CMV specific immunoglobulin G [IgG]), assessed in the
general population, women of childbearing age, and blood and organ
donors were included in this systematic review. Studies were excluded
if they were systematic reviews, surveillance reports, case studies, let-
ters, correspondence, or did not include data on CMV IgG. Studies
were also excluded if they reported seroprevalence data on high‐riskgroups or children only or had a sample size <80, this was to avoid
low quality studies and selection bias. A full list of the inclusion and
exclusion criteria is available in Appendix B. We translated non‐English
papers by asking colleagues proficient in the language in question or
by using “google translate.”
For studies from the United States, we considered the national
health and nutrition examination survey (NHANES) as a representative
sample of the general population.17 Nevertheless, the same full text
screening was applied for all studies from the United States, but only
original data from NHANES were included.2.2 | Data extraction
Following full text review, we extracted the following variables from
each study: study characteristics (number of participants, study dates,
and location), participant characteristics (age, sex, population group),
sample size and number of positive individuals, or, when the latter was
not specified, CMV seroprevalence. Three population groups were con-
sidered: the general population (healthy individuals), women of reproduc-
tive age (pregnant women and women of reproductive age), and blood
and organ donors. Several studies presented stratified results, which
were merged if data allowed. However, three types of stratification did
not allow merging: different population groups (general population,
women of reproductive age, and/or blood and organ donors); groups
with non‐representative sample sizes; and different sampling timeframes.2.3 | Statistical analysis
We estimated the seroprevalence of CMV infection (IgG seropreva-
lence) by country, World Health Organisation (WHO) region, and glob-
ally, by pooling the data from eligible datasets.
Specifically, we performed a random effects meta‐regression
using population group as fixed effect, and country nested within
WHO region as random effect. The inclusion of population as fixed
effect allowed modelling the systematic differences between the con-
sidered population groups and presenting adjusted estimates per
country for the different population groups. A weighted average of
the country estimates based on population size was used to estimate
the regional and global seroprevalence. Population size estimates for
the year 2015 were obtained from the UN World Populations Pros-
pects 2017 Revision.18 Statistical uncertainty in the meta‐analytic
results was propagated to the regional and global estimates through
10 000 Monte Carlo simulations. All parameters were summarized
by their mean and a 95% uncertainty interval (UI) defined as the
2.5th and 97.5th percentile. The meta‐regressions were performed
using the brms package19 version 1.10.0 for R version 3.4.0.203 | RESULTS
Out of 428 unique citations assessed for full text analysis, 262 studies
met the inclusion criteria (Appendix C) (Figure 1). Twenty‐three publica-
tions from the United States met the inclusion criteria. However, only
the NHANES study was used in the analysis since it was considered a
representative sample of the general population.17 A total of 250 datasets
FIGURE 1 Prisma flowchart of study
selection
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cases, the translation was considered sufficient if it was fully comprehen-
sible and allowed a decision to be made about inclusion in the study.
The seroprevalence in the selected datasets ranged from 18%
among a cohort in Canada to 100% in some studies within Bahrain,
Benin, Egypt, Gambia, Iran, Nepal, Thailand, and Turkey. Similarly,
the sample size ranged from 80 to 1 223 217. Figures 2 and 3 show
the estimated mean seroprevalence per country in women of repro-
ductive age gained from the meta‐regression. The estimated mean
seroprevalence and UI by country and population group can be found
in tabular and graphic form in Appendix D.
Table 1 shows the estimated seroprevalence per WHO region and
globally for the different population groups. The estimated global
mean seroprevalence for the general population was 83% (95%UI:
78‐88). The highest mean seroprevalence of 90% (95%UI: 85‐94)
was estimated in the Eastern Mediterranean region, compared to the
lowest of 66% (95%UI: 56‐74) in the European region. When looking
at the different countries, the highest seroprevalence was estimated
in Turkey with a mean of 96% (95%UI: 93‐98) and the lowest in
Ireland with a mean of 39% (95%UI: 18‐62).
The estimated mean seroprevalence for women of reproductive
age was 86% (95%UI: 83‐89) globally, with the highest mean sero-
prevalence estimated in the Eastern Mediterranean region (92%
(95%UI: 88‐95)) and lowest in the European region (70% (95%UI:
63‐76)). In the different countries, the highest seroprevalence was
estimated in Turkey with a mean of 97% (95%UI: 95‐98) and the low-
est in Ireland with a mean of 44% (95%UI: 23‐67).The global mean seroprevalence for blood and organ donors was
estimated to be 86% (95%UI: 82‐89), again with the highest mean
seroprevalence estimated in the Eastern Mediterranean region (92%
(95%UI: 87‐95)) and in Turkey (96% (95%UI: 94‐98)) and the lowest
in the European region (69% (95%UI: 61‐77)) and Ireland (43%
(95%UI: 22‐66)).4 | DISCUSSION
Our results summarize extensive information on the prevalence of
CMV in different populations around the world. The results are consis-
tent with a socio‐economic link with CMV that has been well
established in multiple studies showing that, at any given age, CMV
prevalence is higher in individuals of lower socio‐economic group.21
It has also been reported that the children of individuals born in a
developing country with a high prevalence of CMV have a lower prev-
alence once they become established in their adopted country.22 It
therefore seems likely that unidentified cultural and behavioural fac-
tors also interact with socio‐economic group.
The observed increased seroprevalence forwomen of reproductive
age is likely because of their exposure to children as reported
previously.21,23 However, the reason behind an increased
seroprevalence among blood donors was counter intuitive, and the
causes are less clear.
These results are important for several reasons. First, they will
help to estimate the burden of disease attributable to congenital
FIGURE 2 Meta‐regression–based estimates of country specific mean seroprevalence and 95% uncertainty interval in women of
reproductive age
FIGURE 3 Estimated global cytomegalovirus seroprevalences in women of reproductive age
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TABLE 1 Estimated cytomegalovirus mean seroprevalence % and
corresponding 95% uncertainty interval in the different World Health








European region 66 (56‐74) 70 (63‐76) 69 (61‐77)
Region of the
Americas
75 (64‐84) 79 (69‐87) 78 (67‐87)
South‐east Asian
region
86 (77‐93) 89 (82‐94) 88 (81‐94)
African region 88 (80‐93) 90 (85‐94) 90 (84‐94)
Western Pacific
region




90 (85‐94) 92 (88‐95) 92 (87‐95)
Global 83 (78‐88) 86 (83‐89) 86 (82‐89)
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Although it is believed that women who acquire primary infection dur-
ing pregnancy are most at risk of delivering babies severely damaged
by intrauterine infection, such women are in a minority in many coun-
tries of the world.24 Instead, most babies are born to women who are
seropositive prior to conceiving because of their abundance in the
community. Even in countries with relatively low seroprevalence, the
majority of babies may be infected as a result of CMV reactivation
or reinfection in the mother.25 A high prevalence of infection in a com-
munity therefore contributes to all three types of maternal infection.26
Vaccine studies have been conducted in seronegative and seropositive
women.27,28
Second, the results may help predict the incidence of CMV infec-
tion and disease after solid organ transplant which may originate from
the donor or the recipient.1 Phase 2 randomized clinical trials have
been conducted with vaccine candidates given to recipients awaiting
solid organ transplant.22,29 The situation is more complex following
stem cell transplantation where vaccine may be given to recipients
or donors or both to take advantage of adoptive transfer of immunity
from a donor with or without prior immunity.30,31
Many countries in the world do not undertake organ transplanta-
tion or stem cell transplantation because high‐technology medicine is
not available. However, it is those same countries that often have a
burden of HIV infection, which allows CMV to become an important
opportunistic infection. CMV may therefore act as an important path-
ogen in patients with impaired immunity whether this results from iat-
rogenic or HIV induced immunosuppression. The incidence of
congenital or perinatal CMV is also greatly increased in women with
underlying HIV infection.32,33
We anticipate that the results presented here will improve under-
standing of diseases attributable to CMV in different parts of the
world and will allow vaccine manufacturers to consider where to
recruit individuals for clinical trials. These may either administer
vaccine to seronegatives to prevent primary infection or administer
vaccine to seropositives to boost immunity.15
This work had some limitations. There was a paucity of prevalence
studies within some countries worldwide and the quality of reported
studies also varied. Many of the studies were focused on adults anddid not provide age or sex‐specific prevalence. The lack of age strati-
fication may be a cause of variation between studies, as CMV sero-
prevalence is known to increase with age.34 Some prevalence data
collected were also country specific, whereas a substantial within‐
country variability could be expected. In large countries with high geo-
graphic variation, seroprevalence estimates may not be representative
of the national level. In some countries, there was a lack of available
up‐to‐date seroepidemiological studies. Relying on data from older
studies may risk generating seroprevalence estimates that do not rep-
resent the current epidemiological state of a country.5 | CONCLUSION
Knowledge of worldwide CMV distribution will be helpful in informing
national health care models of burden of disease and help future vac-
cine development.
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